JanOne (NASDAQ:JAN) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Head to Head Analysis

JanOne (NASDAQ:JAN) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

Institutional & Insider Ownership

6.3% of JanOne shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 3.0% of JanOne shares are held by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares JanOne and Oramed Pharmaceuticals’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JanOne	$39.61 million	0.48	-$7.81 million	N/A	N/A
Oramed Pharmaceuticals	$1.34 million	77.92	$5.53 million	$0.26	9.88

Oramed Pharmaceuticals has lower revenue, but higher earnings than JanOne.

Volatility and Risk

JanOne has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500.

Profitability

This table compares JanOne and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
JanOne	N/A	-359.71%	-70.26%
Oramed Pharmaceuticals	N/A	-3.83%	-2.96%

Analyst Recommendations

This is a summary of current ratings and price targets for JanOne and Oramed Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JanOne	0	0	0	0	N/A
Oramed Pharmaceuticals	0	1	0	0	2.00

Summary

Oramed Pharmaceuticals beats JanOne on 6 of the 8 factors compared between the two stocks.

About JanOne

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.